Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Pulmonology, Isfahan University of Medical Science, Isfahan, Iran.
Front Cell Infect Microbiol. 2022 Feb 23;12:784130. doi: 10.3389/fcimb.2022.784130. eCollection 2022.
Data on the prevalence of bacterial co-infections and secondary infection among adults with COVID-19 admitted to the intensive care unit (ICU) are rare. We aimed to determine the frequency of secondary bacterial infection, antibiotic use, and clinical characteristics in patients admitted to the ICU with severe SARS-CoV-2 pneumonia. This was a retrospective cohort study of adults with severe COVID-19 admitted to two ICUs from March 6 to September 7, 2020 in an academic medical center in Isfahan, Iran. To detect COVID-19, reverse transcription real-time polymerase chain reaction was performed and also typical pattern of CT scan was used for the diagnosis of COVID-19. Data collection included the age, gender, main symptoms, history of underlying disease, demographics, hospital stay, outcomes, and antibiotic regimen of the patient. Antimicrobial susceptibility testing was carried out according to the CLSI guidelines. During the study period, 553 patients were referred to the both ICUs for COVID-19 with severe pneumonia. Secondary bacterial infection was detected in 65 (11.9%) patients. The median age was 69.4 (range 21-95) years; 42 (63.6%) were men. Notably, 100% (n = 65) of the patients with superinfection were prescribed empirical antibiotics before first positive culture, predominantly meropenem (86.2%) with a median duration of 12 (range 2-32) days and levofloxacin (73.8%) with a median duration of nine (range 2-24) days. Most prevalent causative agents for secondary bacterial infection were (n = 44) and (n = 33). Most patients with secondary bacterial infection showed extensive drug-resistance. The mortality among patients who acquired superinfections was 83% against an overall mortality of 38.1% in total admitted COVID-19 patients. We found a high prevalence of carbapenem-resistant Gram-negative bacilli in COVID-19 patients admitted to our ICUs, with a high proportion of followed by . These findings emphasize the importance of implementation of strict infection control measures and highlight the role of antimicrobial stewardship during a pandemic.
关于因 COVID-19 入住重症监护病房(ICU)的成年人的细菌合并感染和继发感染的流行数据十分罕见。我们旨在确定因严重 SARS-CoV-2 肺炎入住 ICU 的患者中继发细菌感染、抗生素使用和临床特征的频率。这是一项回顾性队列研究,纳入了 2020 年 3 月 6 日至 9 月 7 日期间,伊朗伊斯法罕一所学术医学中心的 2 个 ICU 中因 COVID-19 入住的成年人。为了检测 COVID-19,进行了逆转录实时聚合酶链反应,也使用 CT 扫描的典型模式来诊断 COVID-19。数据收集包括患者的年龄、性别、主要症状、潜在疾病史、人口统计学、住院时间、结局和抗生素方案。根据 CLSI 指南进行了抗生素药敏试验。在研究期间,553 例因 COVID-19 合并严重肺炎被转诊至这 2 个 ICU。65 例(11.9%)患者检测到继发细菌感染。中位年龄为 69.4 岁(范围为 21-95 岁);42 例(63.6%)为男性。值得注意的是,100%(n=65)继发感染的患者在首次阳性培养前接受了经验性抗生素治疗,主要是美罗培南(86.2%),中位疗程为 12 天(范围为 2-32 天),左氧氟沙星(73.8%),中位疗程为 9 天(范围为 2-24 天)。继发细菌感染的最常见病原体是 (n=44)和 (n=33)。大多数继发细菌感染的患者表现出广泛耐药。继发感染患者的死亡率为 83%,而总的 COVID-19 患者死亡率为 38.1%。我们发现入住 ICU 的 COVID-19 患者中耐碳青霉烯类革兰氏阴性杆菌的流行率很高,其中以 为主,其次是 。这些发现强调了实施严格感染控制措施的重要性,并突出了在大流行期间抗菌药物管理的作用。